Stephen Dale - Jan 29, 2024 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Medical Officer
Signature
Teresa Bair, Attorney-in-fact for Stephen Dale
Stock symbol
KURA
Transactions as of
Jan 29, 2024
Transactions value $
-$231,396
Form type
4
Date filed
1/31/2024, 05:30 PM
Previous filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Sale -$78.3K -4.4K -8.66% $17.80 46.4K Jan 29, 2024 Direct F1
transaction KURA Common Stock Sale -$49.1K -2.76K -5.94% $17.80 43.6K Jan 29, 2024 Direct F2
transaction KURA Common Stock Sale -$104K -4.83K -11.06% $21.55 38.8K Jan 30, 2024 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.
F2 Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23.
F3 This transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2022.
F4 This transaction was executed in multiple trades at prices ranging from $18.53 to $22.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.